{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-24-000054","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.375347+00:00","generated_at":"2026-06-03T02:56:05.423747+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LivaNova Q1 revenue $294.9M (+12% YoY); raises FY2024 guidance; OSPREY study positive","bullets":["Q1 revenue $294.9M, up 12.0% reported, 12.4% constant-currency YoY; adjusted EPS $0.73 vs GAAP loss $0.78.","Cardiopulmonary and Neuromodulation each grew double-digit; ACS wind down on track for end-2024.","Raised full-year 2024 revenue and adjusted diluted EPS guidance (exact figures not in excerpt).","Positive predictive outcome in OSPREY obstructive sleep apnea study; enrollment completed.","Closed $345M 2.50% convertible notes due 2029; repurchased $230M exchangeable notes due 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-24-000054","json":"https://secwatch.observer/filing/0001639691-24-000054.json","markdown":"https://secwatch.observer/filing/0001639691-24-000054.md","text":"https://secwatch.observer/filing/0001639691-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/0001639691-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/livn-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:56:05.423747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9be67fd7ebd62ebe7d65c0a2548856ccf0dc9e3b","claim":"LivaNova PLC reported quarter ended March 31, 2024 results: revenue $294.9 million. Guidance raised.","evidence_excerpt":"quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) • First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/0001639691-24-000054-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$294.9 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b1df27c0a497112a27a33bcbbb6c862c7ec023f5","claim":"LivaNova PLC reported first quarter 2024 results: EPS First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73.","evidence_excerpt":"First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/0001639691-24-000054-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"EPS","value":"First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}